ATE383849T1 - Transdermale pharmazeutische zusammensetzung - Google Patents
Transdermale pharmazeutische zusammensetzungInfo
- Publication number
- ATE383849T1 ATE383849T1 AT04769091T AT04769091T ATE383849T1 AT E383849 T1 ATE383849 T1 AT E383849T1 AT 04769091 T AT04769091 T AT 04769091T AT 04769091 T AT04769091 T AT 04769091T AT E383849 T1 ATE383849 T1 AT E383849T1
- Authority
- AT
- Austria
- Prior art keywords
- transdermal
- pharmaceutical composition
- transdermal pharmaceutical
- trioleate
- glyceryl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 abstract 2
- 229940074928 isopropyl myristate Drugs 0.000 abstract 2
- 239000004973 liquid crystal related substance Substances 0.000 abstract 2
- 229960004063 propylene glycol Drugs 0.000 abstract 2
- 235000013772 propylene glycol Nutrition 0.000 abstract 2
- 229940117972 triolein Drugs 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0303313A HUP0303313A2 (hu) | 2003-10-09 | 2003-10-09 | Transzdermális gyógyszerkészítmények |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE383849T1 true ATE383849T1 (de) | 2008-02-15 |
Family
ID=90001702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04769091T ATE383849T1 (de) | 2003-10-09 | 2004-10-06 | Transdermale pharmazeutische zusammensetzung |
Country Status (13)
Country | Link |
---|---|
US (1) | US7728042B2 (de) |
EP (1) | EP1673063B1 (de) |
JP (1) | JP4884223B2 (de) |
AT (1) | ATE383849T1 (de) |
DE (1) | DE602004011374T2 (de) |
DK (1) | DK1673063T3 (de) |
EA (1) | EA009900B1 (de) |
ES (1) | ES2300820T3 (de) |
HU (1) | HUP0303313A2 (de) |
NO (1) | NO20062053L (de) |
PL (1) | PL1673063T3 (de) |
RS (2) | RS20060249A (de) |
WO (1) | WO2005032514A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050238672A1 (en) * | 2004-04-27 | 2005-10-27 | Nimni Marcel E | Antifungal drug delivery |
WO2006118246A1 (ja) * | 2005-04-28 | 2006-11-09 | Japan Science And Technology Agency | 経皮吸収促進剤 |
FR2900575B1 (fr) * | 2006-05-05 | 2008-10-17 | Anteis Sa | Gel biocompatible a liberation controlee, son procede de preparation et son utilisation |
HUP0700828A2 (en) * | 2007-12-20 | 2010-01-28 | Richter Gedeon Nyrt | Transdermal pharmaceutical compositions containing tolperisone alone and in combination |
ES2326721B1 (es) * | 2008-01-04 | 2010-07-16 | Endor Nanotechnologies, S.L. | Conjugado de acido hialuronico para el tratamiento cosmetico y procedimiento de preparacion. |
WO2010069519A1 (en) * | 2008-12-18 | 2010-06-24 | Merz Pharma Gmbh & Co. Kgaa | Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7 |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
AU2011223807B2 (en) * | 2010-03-02 | 2016-05-12 | Fervent Pharmaceuticals, Llc | Methods and compositions for treating or preventing symptoms of hormonal variations |
US8461102B2 (en) | 2010-03-02 | 2013-06-11 | George E. Royster, JR. | Methods and compositions for treating and preventing symptoms of hormonal variations |
CN103476250A (zh) | 2010-08-18 | 2013-12-25 | 德玛医药 | 改善未达最佳给药的化合物包括取代的己糖醇比如卫康醇与二乙酰二脱水卫矛醇的治疗效果的组合物和方法 |
US9114258B2 (en) | 2011-01-04 | 2015-08-25 | Kato Medical Systems Llc | Electrokinetic nerve stimulator |
AU2012389562A1 (en) | 2011-08-17 | 2014-07-24 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of subotimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
EP2804602A4 (de) | 2012-01-20 | 2016-08-10 | Dennis Brown | Verwendung von substituierten hexitolen mit dianhydrogalactitol und analoga zur behandlung von neoplastischen erkrankungen und krebsstammzellen einschliesslich glioblastoma multforme und medulloblastoma |
WO2013169600A1 (en) | 2012-05-09 | 2013-11-14 | Delmar Pharmaceuticals | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
CA2882870C (en) | 2012-08-24 | 2020-12-15 | Integurx Therapeutics, Llc | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
HU230989B1 (hu) * | 2013-01-17 | 2019-08-28 | Gd Photonics Kft. | Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak előállítására és alkalmazása |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
JP6125547B2 (ja) * | 2013-04-24 | 2017-05-10 | あすか製薬株式会社 | 無定形レボノルゲストレル、固体分散体及びそれらの製造方法 |
WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
EP3125920B1 (de) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol oder dibromodulcitol zur behandlung von nicht-kleinzelligen karzinomen von lungenkrebs und eierstockkrebs |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
MX2016013693A (es) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Crema transdermica. |
CN104725370B (zh) * | 2015-03-19 | 2017-03-01 | 天津大学 | 一种长春西汀管状晶体及制备方法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (de) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | Pharmazeutische steroidhormonzusammensetzung |
CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
RU2712918C1 (ru) * | 2019-08-01 | 2020-02-03 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ предотвращения острой боли при выполнении химического плевродеза после радикальных торакопластических операций онкологического характера |
CN112426403B (zh) * | 2020-12-09 | 2021-09-17 | 南京天纵易康生物科技股份有限公司 | 一种口腔溃疡凝胶及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968539A (en) * | 1987-12-01 | 1990-11-06 | Lion Corporation | Liquid crystal membrane |
US6458774B1 (en) * | 1989-02-24 | 2002-10-01 | Richter Gedeon Vegyeszeti Gyar Rt. | Compositions containing hyaluronic acid associates and a process for preparing same |
CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
IT1248666B (it) | 1990-05-30 | 1995-01-26 | Fidia Spa | Gel in forma di film autosupportanti altamente idrati, processo per laloro preparazione e impiego nella terapia di lesioni e/o patologie cutanee |
HU209605B (en) * | 1991-04-15 | 1994-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for production of wather-free transdermal preparation |
US5326566A (en) * | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
TW218849B (de) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
CA2445086C (en) * | 2001-05-01 | 2008-04-08 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions |
WO2002094278A1 (en) * | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
JP2003063996A (ja) * | 2001-08-23 | 2003-03-05 | 禎秀 ▲廣▼▲崎▼ | 皮膚外用剤 |
US6960563B2 (en) * | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
-
2003
- 2003-10-09 HU HU0303313A patent/HUP0303313A2/hu unknown
-
2004
- 2004-10-06 RS YUP-2006/0249A patent/RS20060249A/sr unknown
- 2004-10-06 ES ES04769091T patent/ES2300820T3/es active Active
- 2004-10-06 PL PL04769091T patent/PL1673063T3/pl unknown
- 2004-10-06 EP EP04769091A patent/EP1673063B1/de active Active
- 2004-10-06 RS RS20060249A patent/RS51764B/en unknown
- 2004-10-06 US US10/575,145 patent/US7728042B2/en not_active Expired - Fee Related
- 2004-10-06 WO PCT/HU2004/000092 patent/WO2005032514A1/en active IP Right Grant
- 2004-10-06 DK DK04769091T patent/DK1673063T3/da active
- 2004-10-06 AT AT04769091T patent/ATE383849T1/de active
- 2004-10-06 JP JP2006530614A patent/JP4884223B2/ja not_active Expired - Fee Related
- 2004-10-06 DE DE602004011374T patent/DE602004011374T2/de active Active
- 2004-10-06 EA EA200600750A patent/EA009900B1/ru not_active IP Right Cessation
-
2006
- 2006-05-08 NO NO20062053A patent/NO20062053L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20070264345A1 (en) | 2007-11-15 |
WO2005032514A1 (en) | 2005-04-14 |
PL1673063T3 (pl) | 2008-06-30 |
RS20060249A (en) | 2008-06-05 |
ES2300820T3 (es) | 2008-06-16 |
DE602004011374T2 (de) | 2009-01-08 |
EP1673063B1 (de) | 2008-01-16 |
EA009900B1 (ru) | 2008-04-28 |
NO20062053L (no) | 2006-05-08 |
RS51764B (en) | 2011-12-31 |
US7728042B2 (en) | 2010-06-01 |
HUP0303313D0 (en) | 2003-12-29 |
HUP0303313A2 (hu) | 2005-07-28 |
EP1673063A1 (de) | 2006-06-28 |
JP4884223B2 (ja) | 2012-02-29 |
EA200600750A1 (ru) | 2006-08-25 |
JP2007508287A (ja) | 2007-04-05 |
DK1673063T3 (da) | 2008-05-19 |
DE602004011374D1 (de) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE383849T1 (de) | Transdermale pharmazeutische zusammensetzung | |
IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
HK1140377A1 (en) | Pharmaceutical use of substituted amides | |
TW200637529A (en) | Topical patch cooling preparation and methods for using the same | |
TW200605870A (en) | Topical methadone compositions and methods for using the same | |
BR0108173A (pt) | Composições farmacêuticas de toxina de botulina | |
EA200801492A1 (ru) | Фармацевтическое применение замещенных амидов | |
SG151329A1 (en) | Amido compounds and their use as pharmaceuticals | |
SG163518A1 (en) | Amido compounds and their use as pharmaceuticals | |
MXPA05004404A (es) | Composicion topica para cuidado de la piel. | |
ATE361084T1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
TW200626156A (en) | Amido compounds and their use as pharmaceuticals | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
SE0101387D0 (sv) | Novel compounds | |
DE69902875T2 (de) | Tts enthaltend ein antioxidans | |
EA200970841A1 (ru) | Фармацевтическое применение замещенных амидов | |
JP2007538008A5 (de) | ||
DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
BRPI0620431A8 (pt) | uso de um poliuretano formador de película, preparação farmacêutica líquida, aplicador e emplastro contendo a referida preparação farmacêutica | |
AU2003296692A1 (en) | Lipidic protein-transfer systems and cosmetic/dermatological use thereof | |
TNSN07203A1 (en) | Pharmaceutical compositions for the treatment of cellulite | |
ATE501719T1 (de) | Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten | |
JO2492B1 (en) | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients | |
UA89043C2 (ru) | Амидосоединения и их применение как фармацевтических средств | |
HUP0204180A2 (hu) | Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1673063 Country of ref document: EP |